Atika Capital Management LLC Biohaven Pharmaceutical Holding CO Ltd. Transaction History

Atika Capital Management LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 12, 2021	SELL	$65.78 - $105.02 $3.09 Million - $4.94 Million	-47,000 Closed	0 $0
Q1 2021 May 14, 2021	SELL	$64.07 - $91.75 $6.15 Million - $8.81 Million	-96,000 Reduced 67.13%	47,000 $3.21 Million
Q4 2020 Feb 16, 2021	BUY	$65.07 - $98.24 $943,514 - $1.42 Million	14,500 Added 11.28%	143,000 $12.3 Million
Q3 2020 Nov 13, 2020	SELL	$59.04 - $77.95 $1 Million - $1.33 Million	-17,000 Reduced 11.68%	128,500 $8.35 Million
Q2 2020 Aug 13, 2020	BUY	$29.01 - $74.23 $2.07 Million - $5.31 Million	71,500 Added 96.62%	145,500 $10.6 Million
Q1 2020 May 14, 2020	SELL	$27.51 - $57.29 $302,610 - $630,190	-11,000 Reduced 12.94%	74,000 $2.52 Million
Q4 2019 Feb 14, 2020	BUY	$40.86 - $57.65 $367,740 - $518,850	9,000 Added 11.84%	85,000 $4.63 Million
Q3 2019 Nov 14, 2019	SELL	$37.38 - $49.47 $1.38 Million - $1.83 Million	-36,893 Reduced 32.68%	76,000 $3.17 Million
Q2 2019 Aug 12, 2019	BUY	$39.79 - $67.01 $1.67 Million - $2.81 Million	41,893 Added 59.0%	112,893 $4.94 Million
Q1 2019 May 13, 2019	BUY	$34.52 - $53.29 $2.45 Million - $3.78 Million	71,000 New	71,000 $3.66 Million

785K

Ticker BHVN
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,645,000
Market Cap $3.65B
Description
Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavege...

Get notified when there are updates to the investment portfolio of Atika Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Atika Capital Management LLC with notifications on news.